# IHP THERAPEUTICS, INC.: A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | IHP THERAPEUTICS, INC. |
| Location | San Carlos, CA |
| Project | A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease |
| Project number | 5UH3NS134781-03 |
| Mechanism | UH3 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $433,322 |
| Awarded | 2026-09-07 |
| Project period | 2023-09-18 to 2027-08-31 |
| UEI | MASZJLS7DHK3 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11402594). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.